BMP Sunstone Reports Third Quarter 2008 Financi...(ble 1: Non-GAAP to GAAP Net Income Recon...)

Three Months Ended Nine Months Ended

September 30, 2008 September 30, 2008

(amounts in thousands, except

per share amounts)

Non-GAAP Net Income (Loss) $1,899 $3,465

Non-GAAP EPS $0.05 $0.09

Stock Based Compensation 636 1,816

Amortization of Debt Discount

and Issuance Cost 977 2,931

Amortization Related to

Acquisitions 1,102 3,279

GAAP Net Income (Loss) ($816) ($4,561)

GAAP EPS ($0.02) ($0.12)

David Gao, Chief Executive Officer of BMP Sunstone, stated, "Once again, we delivered another quarter of strong growth from each division of our Company. During the quarter, we successfully completed the acquisition of 63.3 percent of Rongheng, which provides us with direct access to the Shanghai market - the largest pharmaceutical market in China. We have taken steps towards integrating Rongheng into our national distribution network and we intend to realize the sales potential of our proprietary products."

Mr. Gao continued, "In our existing businesses, both BMP China and Sunstone generated solid growth in the third quarter. Sunstone has historically faced seasonal weakness in the third quarter given that a significant portion of its sales are generated from its cold medicine portfolio. This year, during the third quarter, Sunstone's and Wanwei's sales were also impacted by government restrictions in and around the Beijing area during the Summer Olympics. In our products businesses, Ferriprox has gained significant traction in sales since its launch on June 28, 2008. We are pleased to see improvement demonstrated in both sales and o
'/>"/>